Cullinan Historical Balance Sheet

CGEM Stock

USD 8.09 0.21 2.53%

Trend analysis of Cullinan Oncology LLC balance sheet accounts such as Total Current Liabilities of 32.2 M, Other Liabilities of 55.6 K or Accounts Payable of 2 M provides information on Cullinan Oncology's total assets, liabilities, and equity, which is the actual value of Cullinan Oncology LLC to its prevalent stockholders. By breaking down trends over time using Cullinan Oncology balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cullinan Oncology LLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cullinan Oncology LLC is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

About Cullinan Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cullinan Oncology LLC at a specified time, usually calculated after every quarter, six months, or one year. Cullinan Oncology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cullinan Oncology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cullinan currently owns. An asset can also be divided into two categories, current and non-current.

Cullinan Oncology Balance Sheet Chart

At this time, Cullinan Oncology's Total Stockholder Equity is very stable compared to the past year. As of the 28th of March 2025, Net Tangible Assets is likely to grow to about 646 M, though Retained Earnings are likely to grow to (349.8 M).

Total Assets Total Current Liabilities Other Liab Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Cullinan Oncology assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cullinan Oncology LLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Cullinan Oncology balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cullinan Oncology LLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Cullinan Oncology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cullinan Oncology LLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Cullinan Oncology's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	22.5M	28.1M	30.6M	32.2M
Total Assets	561.1M	484.2M	621.8M	652.9M

Total Current Liabilities Total Assets

Cullinan Oncology balance sheet Correlations

	Total Assets	Total Current Liabilities	Other Liab	Accounts Payable	Other Current Assets	Total Liab	Common Stock	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Cash	Other Assets	Long Term Debt	Net Receivables	Short Long Term Debt	Total Current Assets	Short Term Debt	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total
Total Assets		0.97	-0.53	0.42	0.96	0.11	-0.51	0.96	0.96	-0.88	0.67	0.25	-0.63	0.74	-0.64	0.98	0.43	0.93	0.75	-0.58	0.85	0.2	0.94	0.97	0.89	-0.37
Total Current Liabilities	0.97		-0.5	0.46	0.94	0.18	-0.48	0.91	0.92	-0.9	0.51	0.09	-0.6	0.71	-0.62	0.97	0.37	0.97	0.75	-0.41	0.77	0.31	0.89	0.94	0.86	-0.28
Other Liab	-0.53	-0.5		-0.38	-0.48	-0.38	0.67	-0.41	-0.41	0.45	-0.42	-0.24	0.81	-0.75	0.81	-0.54	-0.48	-0.43	-0.33	0.34	-0.37	-0.24	-0.5	-0.44	-0.57	-0.02
Accounts Payable	0.42	0.46	-0.38		0.37	0.82	-0.52	0.17	0.17	-0.32	0.47	0.49	-0.46	0.5	-0.48	0.48	0.47	0.26	0.17	-0.44	0.18	0.94	0.47	0.23	0.6	0.62
Other Current Assets	0.96	0.94	-0.48	0.37		0.06	-0.45	0.93	0.94	-0.95	0.51	0.3	-0.58	0.69	-0.6	0.92	0.34	0.95	0.59	-0.41	0.86	0.15	0.87	0.95	0.84	-0.4
Total Liab	0.11	0.18	-0.38	0.82	0.06		-0.61	-0.18	-0.17	-0.12	0.13	0.2	-0.45	0.5	-0.47	0.17	0.51	0.01	-0.1	-0.08	-0.07	0.87	0.1	-0.1	0.42	0.86
Common Stock	-0.51	-0.48	0.67	-0.52	-0.45	-0.61		-0.32	-0.33	0.41	-0.47	-0.32	0.8	-0.94	0.85	-0.55	-0.91	-0.37	-0.3	0.38	-0.28	-0.37	-0.51	-0.38	-0.64	-0.19
Total Stockholder Equity	0.96	0.91	-0.41	0.17	0.93	-0.18	-0.32		1.0	-0.83	0.62	0.18	-0.49	0.59	-0.5	0.92	0.27	0.92	0.76	-0.54	0.86	-0.05	0.9	0.99	0.76	-0.61
Net Tangible Assets	0.96	0.92	-0.41	0.17	0.94	-0.17	-0.33	1.0		-0.84	0.59	0.17	-0.49	0.59	-0.5	0.92	0.27	0.94	0.77	-0.52	0.84	-0.04	0.9	1.0	0.75	-0.61
Retained Earnings	-0.88	-0.9	0.45	-0.32	-0.95	-0.12	0.41	-0.83	-0.84		-0.27	-0.14	0.54	-0.66	0.55	-0.8	-0.27	-0.94	-0.44	0.17	-0.87	-0.17	-0.7	-0.87	-0.79	0.31
Cash	0.67	0.51	-0.42	0.47	0.51	0.13	-0.47	0.62	0.59	-0.27		0.6	-0.49	0.54	-0.51	0.68	0.53	0.36	0.6	-0.99	0.48	0.2	0.8	0.59	0.64	-0.18
Other Assets	0.25	0.09	-0.24	0.49	0.3	0.2	-0.32	0.18	0.17	-0.14	0.6		-0.28	0.29	-0.3	0.22	0.36	-0.01	-0.17	-0.61	0.28	0.22	0.37	0.16	0.34	0.08
Long Term Debt	-0.63	-0.6	0.81	-0.46	-0.58	-0.45	0.8	-0.49	-0.49	0.54	-0.49	-0.28		-0.88	1.0	-0.64	-0.51	-0.52	-0.39	0.39	-0.45	-0.29	-0.59	-0.53	-0.68	-0.02
Net Receivables	0.74	0.71	-0.75	0.5	0.69	0.5	-0.94	0.59	0.59	-0.66	0.54	0.29	-0.88		-0.91	0.75	0.8	0.63	0.45	-0.43	0.56	0.32	0.68	0.64	0.79	0.0
Short Long Term Debt	-0.64	-0.62	0.81	-0.48	-0.6	-0.47	0.85	-0.5	-0.5	0.55	-0.51	-0.3	1.0	-0.91		-0.67	-0.58	-0.53	-0.41	0.42	-0.45	-0.3	-0.62	-0.54	-0.7	-0.03
Total Current Assets	0.98	0.97	-0.54	0.48	0.92	0.17	-0.55	0.92	0.92	-0.8	0.68	0.22	-0.64	0.75	-0.67		0.48	0.91	0.82	-0.6	0.72	0.27	0.97	0.94	0.89	-0.3
Short Term Debt	0.43	0.37	-0.48	0.47	0.34	0.51	-0.91	0.27	0.27	-0.27	0.53	0.36	-0.51	0.8	-0.58	0.48		0.25	0.29	-0.47	0.21	0.31	0.48	0.31	0.55	0.16
Other Current Liab	0.93	0.97	-0.43	0.26	0.95	0.01	-0.37	0.92	0.94	-0.94	0.36	-0.01	-0.52	0.63	-0.53	0.91	0.25		0.7	-0.27	0.8	0.12	0.81	0.95	0.77	-0.43
Property Plant And Equipment Net	0.75	0.75	-0.33	0.17	0.59	-0.1	-0.3	0.76	0.77	-0.44	0.6	-0.17	-0.39	0.45	-0.41	0.82	0.29	0.7		-0.57	0.41	0.05	0.81	0.77	0.58	-0.43
Net Debt	-0.58	-0.41	0.34	-0.44	-0.41	-0.08	0.38	-0.54	-0.52	0.17	-0.99	-0.61	0.39	-0.43	0.42	-0.6	-0.47	-0.27	-0.57		-0.4	-0.17	-0.75	-0.51	-0.56	0.17
Non Current Assets Total	0.85	0.77	-0.37	0.18	0.86	-0.07	-0.28	0.86	0.84	-0.87	0.48	0.28	-0.45	0.56	-0.45	0.72	0.21	0.8	0.41	-0.4		-0.01	0.68	0.85	0.71	-0.45
Non Currrent Assets Other	0.2	0.31	-0.24	0.94	0.15	0.87	-0.37	-0.05	-0.04	-0.17	0.2	0.22	-0.29	0.32	-0.3	0.27	0.31	0.12	0.05	-0.17	-0.01		0.22	0.02	0.39	0.76
Cash And Short Term Investments	0.94	0.89	-0.5	0.47	0.87	0.1	-0.51	0.9	0.9	-0.7	0.8	0.37	-0.59	0.68	-0.62	0.97	0.48	0.81	0.81	-0.75	0.68	0.22		0.91	0.86	-0.34
Common Stock Total Equity	0.97	0.94	-0.44	0.23	0.95	-0.1	-0.38	0.99	1.0	-0.87	0.59	0.16	-0.53	0.64	-0.54	0.94	0.31	0.95	0.77	-0.51	0.85	0.02	0.91		0.79	-0.55
Common Stock Shares Outstanding	0.89	0.86	-0.57	0.6	0.84	0.42	-0.64	0.76	0.75	-0.79	0.64	0.34	-0.68	0.79	-0.7	0.89	0.55	0.77	0.58	-0.56	0.71	0.39	0.86	0.79		-0.01
Non Current Liabilities Total	-0.37	-0.28	-0.02	0.62	-0.4	0.86	-0.19	-0.61	-0.61	0.31	-0.18	0.08	-0.02	0.0	-0.03	-0.3	0.16	-0.43	-0.43	0.17	-0.45	0.76	-0.34	-0.55	-0.01

Click cells to compare fundamentals

Cullinan Oncology Account Relationship Matchups

Cullinan Oncology balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	214.7M	437.2M	561.1M	484.2M	621.8M	652.9M
Total Current Liabilities	14.3M	11.7M	22.5M	28.1M	30.6M	32.2M
Accounts Payable	9.7M	3.2M	2.7M	2.5M	1.7M	2.0M
Other Current Assets	4.1M	12.2M	7.2M	13.1M	15.7M	16.5M
Total Liab	291.0M	11.8M	26.1M	30.3M	31.5M	54.1M
Total Stockholder Equity	(77.6M)	422.6M	535.0M	453.7M	590.3M	619.8M
Net Tangible Assets	(40.8M)	(77.6M)	425.0M	535.0M	615.3M	646.0M
Retained Earnings	(93.3M)	(158.9M)	(47.7M)	(200.9M)	(368.2M)	(349.8M)
Cash	168.2M	430.9M	550.1M	98.4M	83.0M	142.8M
Total Current Assets	212.3M	296.6M	474.5M	480.2M	414.7M	435.4M
Other Current Liab	4.6M	8.6M	14.0M	24.2M	27.7M	29.0M
Property Plant And Equipment Net	130K	77K	5.3M	3.5M	2.4M	1.9M
Net Debt	(168.2M)	(430.9M)	(544.9M)	(94.8M)	(80.9M)	(84.9M)
Non Current Assets Total	2.4M	140.6M	86.6M	4.0M	207.2M	217.5M
Cash And Short Term Investments	210.2M	430.9M	550.1M	467.1M	399.0M	344.1M
Short Term Investments	42.0M	230.7M	311.1M	368.6M	316.0M	204.9M
Liabilities And Stockholders Equity	214.7M	434.8M	561.1M	484.2M	621.8M	385.3M
Non Current Liabilities Total	276.7M	65K	3.6M	2.2M	849K	806.6K
Other Stockholder Equity	15.7M	584.7M	585.3M	654.7M	958.7M	1.0B
Net Invested Capital	(77.6M)	425.0M	535.2M	453.7M	590.3M	619.8M
Property Plant And Equipment Gross	130K	309K	5.4M	3.9M	3.0M	2.1M
Accumulated Other Comprehensive Income	(2K)	(838K)	(2.6M)	(129K)	(133K)	(139.7K)
Net Working Capital	198.0M	284.8M	452.0M	452.1M	384.0M	298.8M
Property Plant Equipment	182K	130K	77K	1.2M	1.4M	1.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:

How To Invest In Cullinan

Details

Is Cullinan Stock a good investment?

Details

What is Cullinan Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the CEOs Directory module to screen CEOs from public companies around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.78)

Return On Assets

(0.22)

Return On Equity

(0.32)

The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cullinan Historical Balance Sheet

About Cullinan Balance Sheet Analysis

Cullinan Oncology Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Cullinan Oncology balance sheet Correlations

Cullinan Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cullinan Oncology balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Common Stock Total Equity	+ 1.0	Net Tangible Assets
Short Long Term Debt	+ 1.0	Long Term Debt
Common Stock Total Equity	+ 0.99	Total Stockholder Equity
Total Current Assets	+ 0.98	Total Assets
Total Current Liabilities	+ 0.97	Total Assets

Net Debt	- 0.99	Cash
Retained Earnings	- 0.95	Other Current Assets
Other Current Liab	- 0.94	Retained Earnings
Net Receivables	- 0.94	Common Stock
Short Long Term Debt	- 0.91	Net Receivables
Short Term Debt	- 0.91	Common Stock